Cargando…
Ig-like ACE2 protein therapeutics: A revival in development during the COVID-19 pandemic
While the potential therapeutic utility of angiotensin-converting enzyme 2 (ACE2) is well established, the clinical development of ACE2 drugs has been limited, likely due in part to the short half-life of the protein. In contrast, Ig-like ACE2 fusion proteins have exhibited greatly extended plasma h...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Taylor & Francis
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7531491/ https://www.ncbi.nlm.nih.gov/pubmed/32546047 http://dx.doi.org/10.1080/19420862.2020.1782600 |